Matches in SemOpenAlex for { <https://semopenalex.org/work/W3086765391> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W3086765391 endingPage "S20" @default.
- W3086765391 startingPage "S20" @default.
- W3086765391 abstract "Recent improvements in the treatment of non-small cell lung cancer (NSCLC) are largely attributable to early detection, refinements in radiation and surgical techniques, and personalized targeted therapy in patients with oncogenic driver mutations. Accordingly, multidisciplinary collaboration and biomarker testing have become critically important. This study was conducted to identify key specialties involved and describe different roles in the management of NSCLC in Korea. A doctor level cross-sectional survey was conducted with 468 panels in 2019, randomly selected considering a balanced distribution in specialties, regions and institutions. The survey included questions around physicians’ involvement in diagnosis and treatment of cancer. Based on the survey, the number of NSCLC patients they treated, stratified by cancer stage and drug treatment, and the types of biomarker tests, were compared by specialty. Among the surveyed panels, 59 specialists reported treating NSCLC, consisting of 33 pulmonologists, 19 onc-haematologists, and 7 in other specialties. The number of NSCLC patients treated per month averaged 89.12±75.82, 40.84±49.27, and 27.57±33.79 (p=0.002) for pulmonologists, onc-haematologists, and other specialists, respectively; of those NSCLC patients they treated, 70.93%, 81.70%, and 40.93% (p<0.001) were late stage, and 64.57%, 64.95%, and 49.74% (p<0.001) received drug treatment, respectively. Onc-haematologists performed the most biomarker tests (4.53±1.93), followed by other specialists (3.57±2.15) and pulmonologists (3.45±0.94). Most of the pulmonologists tested mutations in ALK (100%), EGFR (100%), and PL-1/PD-L1 (96.97%), but few other biomarkers were tested. All onc-haematologists tested mutations in ALK (100%), EGFR (100%), and PL-1/PD-L1 (100%), and some in BRAF (47.37%) and KRAS (36.84%) additionally. Other specialists tested less for ALK (42.86%), EGFR (85.71%), and PL-1/PD-L1 (57.14%) mutation, but more for KRAS (71.43%) and VEGF (57.14%). Our study suggests that the roles and practices differ in the management of NSCLC by specialty. Further study is needed to reflect patients’ specific medical condition." @default.
- W3086765391 created "2020-09-21" @default.
- W3086765391 creator A5012156598 @default.
- W3086765391 creator A5013276791 @default.
- W3086765391 creator A5018987094 @default.
- W3086765391 creator A5020867061 @default.
- W3086765391 creator A5058707200 @default.
- W3086765391 date "2020-09-01" @default.
- W3086765391 modified "2023-10-16" @default.
- W3086765391 title "PCN81 The Role of Different Specialties in the Management of NON-SMALL CELL LUNG Cancer: Insights from a Real-World Study" @default.
- W3086765391 doi "https://doi.org/10.1016/j.vhri.2020.07.131" @default.
- W3086765391 hasPublicationYear "2020" @default.
- W3086765391 type Work @default.
- W3086765391 sameAs 3086765391 @default.
- W3086765391 citedByCount "0" @default.
- W3086765391 crossrefType "journal-article" @default.
- W3086765391 hasAuthorship W3086765391A5012156598 @default.
- W3086765391 hasAuthorship W3086765391A5013276791 @default.
- W3086765391 hasAuthorship W3086765391A5018987094 @default.
- W3086765391 hasAuthorship W3086765391A5020867061 @default.
- W3086765391 hasAuthorship W3086765391A5058707200 @default.
- W3086765391 hasBestOaLocation W30867653911 @default.
- W3086765391 hasConcept C121608353 @default.
- W3086765391 hasConcept C126322002 @default.
- W3086765391 hasConcept C143998085 @default.
- W3086765391 hasConcept C146357865 @default.
- W3086765391 hasConcept C151730666 @default.
- W3086765391 hasConcept C177713679 @default.
- W3086765391 hasConcept C185592680 @default.
- W3086765391 hasConcept C20387591 @default.
- W3086765391 hasConcept C2776256026 @default.
- W3086765391 hasConcept C2781197716 @default.
- W3086765391 hasConcept C2908861384 @default.
- W3086765391 hasConcept C512399662 @default.
- W3086765391 hasConcept C55493867 @default.
- W3086765391 hasConcept C71924100 @default.
- W3086765391 hasConcept C86803240 @default.
- W3086765391 hasConceptScore W3086765391C121608353 @default.
- W3086765391 hasConceptScore W3086765391C126322002 @default.
- W3086765391 hasConceptScore W3086765391C143998085 @default.
- W3086765391 hasConceptScore W3086765391C146357865 @default.
- W3086765391 hasConceptScore W3086765391C151730666 @default.
- W3086765391 hasConceptScore W3086765391C177713679 @default.
- W3086765391 hasConceptScore W3086765391C185592680 @default.
- W3086765391 hasConceptScore W3086765391C20387591 @default.
- W3086765391 hasConceptScore W3086765391C2776256026 @default.
- W3086765391 hasConceptScore W3086765391C2781197716 @default.
- W3086765391 hasConceptScore W3086765391C2908861384 @default.
- W3086765391 hasConceptScore W3086765391C512399662 @default.
- W3086765391 hasConceptScore W3086765391C55493867 @default.
- W3086765391 hasConceptScore W3086765391C71924100 @default.
- W3086765391 hasConceptScore W3086765391C86803240 @default.
- W3086765391 hasLocation W30867653911 @default.
- W3086765391 hasOpenAccess W3086765391 @default.
- W3086765391 hasPrimaryLocation W30867653911 @default.
- W3086765391 hasRelatedWork W102980731 @default.
- W3086765391 hasRelatedWork W1482345510 @default.
- W3086765391 hasRelatedWork W1967103478 @default.
- W3086765391 hasRelatedWork W2032912323 @default.
- W3086765391 hasRelatedWork W2356105190 @default.
- W3086765391 hasRelatedWork W2372561159 @default.
- W3086765391 hasRelatedWork W2375344515 @default.
- W3086765391 hasRelatedWork W2390152934 @default.
- W3086765391 hasRelatedWork W2937519691 @default.
- W3086765391 hasRelatedWork W3096852753 @default.
- W3086765391 hasVolume "22" @default.
- W3086765391 isParatext "false" @default.
- W3086765391 isRetracted "false" @default.
- W3086765391 magId "3086765391" @default.
- W3086765391 workType "article" @default.